On August 31, 2023, Vaccines ('Vaccines'), an authoritative international journal in the field of vaccines, published an article entitled Effect of Influenza Vaccination on Rate of Influenza Virus Infection in Chinese Military Personnel, 2015-2016: A Cluster Randomized Trial ('2015 -The Effect of Influenza Vaccination on the Infection Rate of Influenza Virus in Chinese Soldiers in 2016: A Cluster Randomized Trial') The results of the research paper showed that SINOVAC Kexing Trivalent Influenza Virus Split Vaccine Anerifu was effective in healthy young people (military) Among them, the vaccine has good immunogenicity and safety and can significantly reduce the risk of influenza.

This study is the first study on the protective effect of influenza vaccine for Chinese military personnel, and also adds strong evidence for the prevention and control of influenza among Chinese military personnel.

Influenza [1] is an acute respiratory infectious disease caused by influenza virus, which seriously endangers the health of the population. The World Health Organization recommends that high-risk groups, high-risk groups and people living in groups receive seasonal influenza vaccines every year to prevent influenza [2]. Due to the relatively dense living environment of active duty military personnel, the risk of influenza outbreaks is always present. Since 1946 [3], the United States has been providing influenza vaccination services to military personnel. Results show that influenza vaccination can reduce the risk of influenza infection among military personnel [4].

However, research on the protective effect of influenza vaccines on military personnel in China is relatively lacking. In order to provide supporting data for China's military vaccination strategies, the Center for Disease Control and Prevention of the Central Theater Command conducted three influenza vaccinations in Beijing, Tianjin, and Hebei Province during the 2015-2016 influenza season. A large-scale, prospective, cluster-randomized, open-label, placebo-controlled study of Amlafo was conducted among local active-duty military personnel .Phase IV clinical trial of protective effect [5].

In this study, 5,445 subjects were vaccinated with 1 dose of Allife within 3 weeks before the start of the influenza epidemic at 3 trial sites, and 6,031 control subjects were not vaccinated against influenza, and they were followed for 6 months.

The results showed that 18 and 87 people in the Anerifu group and the unvaccinated group (control group) were laboratory-confirmed influenza respectively, and the protective effect of Anerifu on laboratory -confirmed influenza was 76.4%; There were 132 and 420 people in the Laifu group and 420 people in the control group, respectively. The protective effect of Anraifu on influenza-like cases was 64.1%. Generally speaking, the tested soldiers had good tolerance to the influenza vaccine.

This study shows that the immunogenicity and safety of the vaccine are good in healthy young people (military personnel) and can significantly reduce the risk of influenza. By getting vaccinated against influenza, military personnel can be effectively protected from influenza.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is China's leading biotech enterprise. With the mission of 'providing vaccines to eliminate diseases for humans', it is committed to the research of human vaccines and related products. Development, production and sales to provide services for global disease prevention and control.

The vaccines developed by SINOVAC mainly include vaccines against viral hepatitis, influenza, pneumonia, polio, chickenpox, mumps and other common infectious diseases, as well as vaccines against SARS, H5N1 avian influenza, H1N1 pandemic influenza, EV71 hand, foot and mouth disease, novel Vaccines for emerging and emerging infectious diseases such as coronavirus infections.

The company's current 4 vaccines have passed World Health Organization pre-certification (inactivated hepatitis A vaccine, Sabin strain inactivated polio vaccine, live attenuated chickenpox vaccine) or are included in the emergency use list (new coronavirus inactivated vaccine). The quality of the vaccines is The management system has been recognized by international organizations and multinational drug regulatory authorities.

SINOVAC is constantly exploring opportunities in the international market and has exported vaccines to dozens of countries and international organizations.

Contact:

Tel: +86-10-8279-9800

Fax: +86-10-6296-6910

Email: sinovac@sinovac.com

(C) 2023 Electronic News Publishing, source ENP Newswire